Yıl: 2020 Cilt: 30 Sayı: 0 Sayfa Aralığı: 36 - 42 Metin Dili: Türkçe DOI: 10.5222/terh.2020.02693 İndeks Tarihi: 30-10-2020

COVID-19 Bulaş Yolları ve Önleme

Öz:
Çin’de 2019 aralık ayında başlayan SARS-CoV-2 virüsünün ve COVID-19 olarak tanımlanan hastalığın neden olduğusalgın, Dünya Sağlık Örgütü tarafından 2020 Mart ayında küresel pandemi olarak ilan edilmiştir. Salgının kaynağınet olarak açıklanamamıştır. Virüsün hayvanlar üzerinde mutasyona uğrayarak insandan insana bulaşma özelliğikazandığı düşünülmektedir. Salgının farklı bölgelerde dağılımı ve sonuçları, iklim, hijyen, nüfus, demografik özellikler, bulaş özellikleri gibi birçok faktöre göre farklılık göstermektedir. Hastalık esas olarak damlacık ve temas yoluylabulaşmaktadır. Ayrıca aerosolların solunması gibi başka yollar da gösterilmiştir. Enfeksiyonun bulaşma riski, maruziyet türü ve süresine, önleyici önlemlerin kullanımına ve olası bireysel faktörlere göre değişir. Henüz COVID-19’atamamen etkili olan bir tedavi ya da koruyucu bir aşı yoktur, ancak tedavi ve aşılarla ilgili çalışmalar devam etmektedir. Virüsün toplum içinde yayılmasını engelleyecek en önemli önlemler el hijyeni, sosyal mesafe ve karantinadır.Daha fazla yayılmayı engellemek için erken tarama, tanı, izolasyon ve tedavi gereklidir. Önleyici stratejiler, hastaların izolasyonu ve enfekte bir hastaya teşhis ve klinik bakım sağlanması sırasında alınması gereken uygun önlemler dahil olmak üzere dikkatli enfeksiyon kontrolüne odaklanır.
Anahtar Kelime:

COVID-19 Transmission and Prevention

Öz:
The epidemic caused by the SARS-CoV-2 virus and the disease identified as COVID-19 infection, which emerged in December 2019 in China, was declared as a global pandemic by the World Health Organization in March 2020. The source of the outbreak has not been clearly explained. It is estimated that the virus mutated on animals and acquired the characteristic feature of human-to-human transmission. The distribution and outcomes of the epidemic in different regions change according to many factors such as climate, hygiene, population, demographic characteristics, health facilities, and transmission characteristics. The disease is transmitted mainly through droplets and contact. Other routes of transmisision as inhalation of aerosols, are also shown. The risk of transmission of infection varies depending on the type and duration of exposure, the use of preventive measures and possible individual factors. There is currently no treatment that is fully effective on COVID-19 or its protective vaccine is not available. However, studies on treatment and vaccines are ongoing. The most important measures to prevent the spread of the virus in society are hand hygiene, social distance and quarantine. Early screening, diagnosis, isolation and treatment are necessary to prevent further spread. Preventive strategies focus on careful infection control, including patient isolation and appropriate measures to be taken during diagnosis and clinical care for an infected patient.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Çetin C, Kara A. Global surveillance, travel, and trade during a pandemic. Turk J Med Sci. 2020;50:527-33. [CrossRef]
  • 2. World Health Organization. WHO announces COVID-19 outbreak a pandemic. 2020. Available from: http://www. euro.who.int/en/health-topics/health-emergencies/ coronavirus-covid-19/news/news/2020/3/who-announcescovid-19-outbreak-a-pandemic Accessed: 6 May 2020
  • 3. Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARSCoV-2 Associated with the COVID-19 Outbreak. Curr Biol. 2020;30(7):1346-51. [CrossRef]
  • 4. Lv L, Li G, Chen J, Liang X, Li Y. Comparative genomic analysis revealed specific mutation pattern between human coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13. bioRxiv. 2020. [CrossRef]
  • 5. Genomic epidemiology of novel coronavirus - Global subsampling. 2019-2020 Available from: https://nextstrain.org/ ncov/global Accessed: 6 May 2020.
  • 6. Petersen E, Gökengin D. SARS-CoV-2 epidemiology and control, different scenarios for Turkey. Turk J Med Sci. 2020;50:509- 14. [CrossRef]
  • 7. Wang FS, Zhang C. What to do next to control the 2019-nCoV epidemic? The Lancet. 2020;395(10222):391-3. [CrossRef]
  • 8. To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565- 74. [CrossRef]
  • 9. Cheng PKC, Wong DA, Tong LKL, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. The Lancet. 2004;363(9422):1699-1700. [CrossRef]
  • 10. Pan Y, Zhang D, Yang P, et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411-2. [CrossRef]
  • 11. Liu Y, Yan LM, Wan L, et al. Viral Dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020. [CrossRef]
  • 12. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92. [CrossRef]
  • 13. World Health Organization Department of Communicable Disease Surveillance and Response. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS) [online]. 2003 Available from: https://www.who.int/ csr/sars/WHOconsensus.pdf Accessed: 6 May 2020.
  • 14. Akın L, Gözel MG. Understanding dynamics of pandemics. Turk J Med Sci. 2020;50:515-9. [CrossRef]
  • 15. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, and Ruian K. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(7). [CrossRef]
  • 16. Li R, Pei S, Chen B et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489-93. [CrossRef]
  • 17. TC Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü. COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi. Ankara;14.04.2020 Available from: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf?type=file Accessed 6 May 2020.
  • 18. Uptodate. Coronovirus disease 2019 (COVID-19): Epidemiology, virolog, clinical features, diagnosis, and prevention. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiologyvirology-clinical-features-diagnosis-and-prevention Accesse: 6 May 2020.
  • 19. Kurtulus B, Ozlu T. New Coronavirus: SARS-CoV-2. Mucosa. 2020;3(1):1-4. [CrossRef]
  • 20. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARSCoV-1. N Engl J Med. 2020;382(16):1564. [CrossRef]
  • 21. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. Emerg Infect Dis. 2020;26(7). [CrossRef]
  • 22. Bourouiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. JAMA. 2020. [CrossRef]
  • 23. World Health Organization. Report of the WHO China joint mission on coronavirus disease 2019 (COVID-19)[online]. 2020. Available from: https://www.who.int/docs/defaultsource/coronaviruse/who-china-joint-mission-on-covid-19- finalreport.pdf Accessed: 6 May 2020
  • 24. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. 2020. [CrossRef]
  • 25. Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. Lancet Infect Dis. 2020. [CrossRef]
  • 26. Backer Jantien A, Klinkenberg Don, Wallinga Jacco. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5). [CrossRef]
  • 27. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020. [CrossRef]
  • 28. G. Kampf , D. Todt , S. Pfaender , E. Steinmann. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246-51. [CrossRef]
  • 29. World Organization for Animal Health. Questions and Answers on the 2019 Coronavirus Disease (COVID-19), section on Surveillance and events in animals. 2020. Available from: https://www.oie.int/en/scientific-expertise/specificinformation-and-recommendations/questions-andanswers-on-2019novel-coronavirus Accessed on May 6, 2020.
  • 30. Güner R, Hasanoğlu İ, Aktaş F. COVID-19: Prevention and control measures in community. Turk J Med Sci. 2020;50:571-7. [CrossRef]
  • 31. Centers for Diseases Control and Prevention. Corona Disease 2019. How to Protect Yourself & Others. 2020 Available from: https://www.cdc.gov/coronavirus/2019-ncov/preventgetting-sick/prevention.html Accessed 6 May 2020
  • 32. Liang T (ed). Handbook of COVID-19 Prevention and Treatment (20.03.2020). Zhejiang, China; 2020 Available from: https://covid19.alibabacloud.com/?spm=a2c65.11461 447.0.0.336b5272F0SUJy#J_8102420620 Accessed 6 May 2020
  • 33. Centers for Diseases Control and Prevention Infection Control Guidance for Healthcare Professionals about Coronavirus (COVID-19) CDC.2020. Available from: https://www.cdc.gov/ coronavirus/2019-ncov/hcp/infection-control.html Accessed 6 May 2020
  • 34. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020. [CrossRef] 35. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Nonspecific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473. [CrossRef]
APA Türken M, köse ş (2020). COVID-19 Bulaş Yolları ve Önleme. , 36 - 42. 10.5222/terh.2020.02693
Chicago Türken Melda,köse şükran COVID-19 Bulaş Yolları ve Önleme. (2020): 36 - 42. 10.5222/terh.2020.02693
MLA Türken Melda,köse şükran COVID-19 Bulaş Yolları ve Önleme. , 2020, ss.36 - 42. 10.5222/terh.2020.02693
AMA Türken M,köse ş COVID-19 Bulaş Yolları ve Önleme. . 2020; 36 - 42. 10.5222/terh.2020.02693
Vancouver Türken M,köse ş COVID-19 Bulaş Yolları ve Önleme. . 2020; 36 - 42. 10.5222/terh.2020.02693
IEEE Türken M,köse ş "COVID-19 Bulaş Yolları ve Önleme." , ss.36 - 42, 2020. 10.5222/terh.2020.02693
ISNAD Türken, Melda - köse, şükran. "COVID-19 Bulaş Yolları ve Önleme". (2020), 36-42. https://doi.org/10.5222/terh.2020.02693
APA Türken M, köse ş (2020). COVID-19 Bulaş Yolları ve Önleme. İzmir Tepecik Eğitim Hastanesi Dergisi, 30(0), 36 - 42. 10.5222/terh.2020.02693
Chicago Türken Melda,köse şükran COVID-19 Bulaş Yolları ve Önleme. İzmir Tepecik Eğitim Hastanesi Dergisi 30, no.0 (2020): 36 - 42. 10.5222/terh.2020.02693
MLA Türken Melda,köse şükran COVID-19 Bulaş Yolları ve Önleme. İzmir Tepecik Eğitim Hastanesi Dergisi, vol.30, no.0, 2020, ss.36 - 42. 10.5222/terh.2020.02693
AMA Türken M,köse ş COVID-19 Bulaş Yolları ve Önleme. İzmir Tepecik Eğitim Hastanesi Dergisi. 2020; 30(0): 36 - 42. 10.5222/terh.2020.02693
Vancouver Türken M,köse ş COVID-19 Bulaş Yolları ve Önleme. İzmir Tepecik Eğitim Hastanesi Dergisi. 2020; 30(0): 36 - 42. 10.5222/terh.2020.02693
IEEE Türken M,köse ş "COVID-19 Bulaş Yolları ve Önleme." İzmir Tepecik Eğitim Hastanesi Dergisi, 30, ss.36 - 42, 2020. 10.5222/terh.2020.02693
ISNAD Türken, Melda - köse, şükran. "COVID-19 Bulaş Yolları ve Önleme". İzmir Tepecik Eğitim Hastanesi Dergisi 30/0 (2020), 36-42. https://doi.org/10.5222/terh.2020.02693